Sophie de Carné Trécesson
Sophie de Carné Trécesson
Autres nomsSophie de Carné, Sophie de Carne
Adresse e-mail validée de
Citée par
Citée par
Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA
MA Coelho, S de Carné Trécesson, S Rana, D Zecchin, C Moore, ...
Immunity 47 (6), 1083-1099. e6, 2017
The cdk5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition
S Courapied, H Sellier, S de Carné Trécesson, A Vigneron, AC Bernard, ...
Journal of Biological Chemistry 285 (35), 26765-26778, 2010
Antibodies against endogenous retroviruses promote lung cancer immunotherapy
KW Ng, J Boumelha, KSS Enfield, J Almagro, H Cha, O Pich, T Karasaki, ...
Nature 616 (7957), 563-573, 2023
Tight sequestration of BH3 proteins by BCL-xL at subcellular membranes contributes to apoptotic resistance
J Pécot, L Maillet, J Le Pen, C Vuillier, S de Carné Trécesson, A Fétiveau, ...
Cell reports 17 (12), 3347-3358, 2016
Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells
A Basseville, L Preisser, S de Carné Trécesson, M Boisdron-Celle, ...
Molecular cancer 10, 1-12, 2011
Escape from p21-mediated oncogene-induced senescence leads to cell dedifferentiation and dependence on anti-apoptotic Bcl-xL and MCL1 proteins
S de Carné Trécesson, Y Guillemin, A Bélanger, AC Bernard, L Preisser, ...
Journal of Biological Chemistry 286 (15), 12825-12838, 2011
Genomic–transcriptomic evolution in lung cancer and metastasis
C Martínez-Ruiz, JRM Black, C Puttick, MS Hill, J Demeulemeester, ...
Nature 616 (7957), 543-552, 2023
Irinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1
B Jonchère, A Vétillard, B Toutain, D Lam, AC Bernard, C Henry, ...
Oncotarget 6 (1), 409, 2015
BCL-XL directly modulates RAS signalling to favour cancer cell stemness
S Carné Trécesson, F Souazé, A Basseville, AC Bernard, J Pécot, ...
Nature Communications 8 (1), 1123, 2017
Protect and serve: Bcl-2 proteins as guardians and rulers of cancer cell survival
F Braun, S de Carné Trécesson, J Bertin-Ciftci, P Juin
Cell Cycle 12 (18), 2937-2947, 2013
An immunogenic model of KRAS-mutant lung cancer enables evaluation of targeted therapy and immunotherapy combinations
J Boumelha, S de Carné Trécesson, EK Law, P Romero-Clavijo, ...
Cancer research 82 (19), 3435-3448, 2022
Carcinoma-associated fucosylated antigens are markers of the epithelial state and can contribute to cell adhesion through CLEC17A (Prolectin)
A Breiman, MDL Robles, S de Carné Trécesson, K Echasserieau, ...
Oncotarget 7 (12), 14064, 2016
RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma
P East, GP Kelly, D Biswas, M Marani, DC Hancock, T Creasy, ...
Nature communications 13 (1), 5632, 2022
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance
DR Caswell, P Gui, MK Mayekar, EK Law, O Pich, C Bailey, J Boumelha, ...
Nature Genetics 56 (1), 60-73, 2024
Combining RASG12C(ON) inhibitor with SHP2 inhibition sensitises immune excluded lung tumours to immune checkpoint blockade: a strategy for turning cold …
P Anastasiou, C Moore, S Rana, A de Castro, M Tomaschko, J Boumelha, ...
bioRxiv, 2024.01. 15.575765, 2024
In vivo CRISPR screen identifies KRAS-induced COX-2 as a driver of immune evasion and immunotherapy resistance in lung cancer
J Boumelha, A de Castro, N Bah, H Cha, S de Carné Trécesson, S Rana, ...
bioRxiv, 2023.04. 13.536740, 2023
Oncogène RAS et Cancer Colorectal: Étude de la Réponse au Stress Oncogénique et de l'Échappement à la Sénescence
S de Carné Trécesson
Université d'Angers, 2010
RAS orchestrates an increase of interstitial adenosine in lung adenocarcinoma to promote immune evasion
S de Carné Trécesson, J Boumhela, C Moore, D Caswell, ...
European Journal of Cancer 138, S20-S21, 2020
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–18